Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that initial clinical results and preclinical data for zovegalisib (RLY-2608) in vascular anomalies will be presented at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026, taking place May 19-22, 2026, in Philadelphia. The company anticipates reporting clinical data on approximately 20 efficacy-evaluable patients. Late Breaking Clinical Abstract:Abstract Title: Initial Results of Zovegalisib (RLY-2608), a Mutant-selective PI3Ka Inhibitor in Adult and Pediatric Patients with PIK3CA-Driven Vascular Malformations Abstract Number: 488Session: Late Breaking Abstract SessionDate/Time: Wednesday, May 20, 4:30 p.m. ET Preclinical Abstract:Abstract Title: Zovegalisib (RLY-2608), a Nove
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Relay Therapeutics (RLAY) is now covered by JonesTrading. They set a "hold" rating and a $18.00 price target on the stock.MarketBeat
- Relay Therapeutics (RLAY) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Relay Therapeutics (RLAY) had its price target raised by Barclays PLC from $17.00 to $21.00. They now have an "overweight" rating on the stock.MarketBeat
- Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains? [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics (RLAY) Is Up 30.6% After Expanding Zovegalisib Into Vascular Anomalies Data Reveal [Yahoo! Finance]Yahoo! Finance
RLAY
Earnings
- 2/26/26 - Beat
RLAY
Sec Filings
- 4/16/26 - Form PRE
- 4/13/26 - Form SCHEDULE
- 4/9/26 - Form 4
- RLAY's page on the SEC website